Effective management of advanced colon cancer genotyping MSS/MSI-L with KRAS mutation using nivolumab plus ipilimumab combined with regorafenib and irinotecan: A case report

Cui, Y; Ou, Y; Luo, Y; Yu, J; Lin, Y; Chen, S

Effective management of advanced colon cancer genotyping MSS/MSI-L with KRAS mutation using nivolumab plus ipilimumab combined with regorafenib and irinotecan: A case report

Cui, Y Ou, Y Luo, Y Yu, J Lin, Y

Chen, S

Permalink

Publication Type:: Journal Article
Citation:: SAGE Open Medical Case Reports, 2021
Issue Date:: 2021-06-23

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download Published VersionAdobe PDF (3.62 MB)

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	Cui, Y
dc.contributor.author	Ou, Y
dc.contributor.author	Luo, Y
dc.contributor.author	Yu, J
dc.contributor.author	Lin, Y https://orcid.org/0000-0002-4637-9701
dc.contributor.author	Chen, S
dc.date.accessioned	2021-06-22T23:35:14Z
dc.date.available	2021-06-02
dc.date.available	2021-06-22T23:35:14Z
dc.date.issued	2021-06-23
dc.identifier.citation	SAGE Open Medical Case Reports, 2021
dc.identifier.uri	http://hdl.handle.net/10453/149723
dc.description.abstract	Microsatellite stable (MSS)/ microsatellite instable-low (MSI-L) is the most common colorectal cancer (CRC) genotype, counting for approximately 85% of CRC patients. Treatment of advanced MSS)/MSI-L CRC is difficult and successful pharmacological treatment options are currently lacking. Here, we report a case of a 37-year-old man with advanced CRC genotyping MSS/MSI-L with a KRAS (G12V) mutation. Following palliative surgery, the patient did not response to the common recommended chemotherapy FOLFIRI regimen and other chemotherapy options. Finally, the patient was successfully treated using a unique combinational immunotherapy, using nivolumab plus ipilimumab combined with regorafenib and irinotecan. Significant improvement in the Karnofsky performance status (KPS) scores, liver function and well-being, reduction in serum tumor biomarkers, and reduction in the size of multiple liver metastatic tumors was evident. This report provides a rare case in which a unique and effective combinational immunotherapy for refractory advanced colon cancer patients is discussed. It encourages further research into combined immunotherapy for immuno-insensitive colon cancer patients.
dc.language	en
dc.relation.ispartof	SAGE Open Medical Case Reports
dc.rights	info:eu-repo/semantics/openAccess
dc.title	Effective management of advanced colon cancer genotyping MSS/MSI-L with KRAS mutation using nivolumab plus ipilimumab combined with regorafenib and irinotecan: A case report
dc.type	Journal Article
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Life Sciences
utslib.copyright.status	open_access	*
pubs.consider-herdc	false
dc.date.updated	2021-06-22T23:35:12Z
pubs.publication-status	Accepted

Abstract:

Microsatellite stable (MSS)/ microsatellite instable-low (MSI-L) is the most common colorectal cancer (CRC) genotype, counting for approximately 85% of CRC patients. Treatment of advanced MSS)/MSI-L CRC is difficult and successful pharmacological treatment options are currently lacking. Here, we report a case of a 37-year-old man with advanced CRC genotyping MSS/MSI-L with a KRAS (G12V) mutation. Following palliative surgery, the patient did not response to the common recommended chemotherapy FOLFIRI regimen and other chemotherapy options. Finally, the patient was successfully treated using a unique combinational immunotherapy, using nivolumab plus ipilimumab combined with regorafenib and irinotecan. Significant improvement in the Karnofsky performance status (KPS) scores, liver function and well-being, reduction in serum tumor biomarkers, and reduction in the size of multiple liver metastatic tumors was evident. This report provides a rare case in which a unique and effective combinational immunotherapy for refractory advanced colon cancer patients is discussed. It encourages further research into combined immunotherapy for immuno-insensitive colon cancer patients.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/149723